IL23A, interleukin 23 subunit alpha, 51561

N. diseases: 427; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE There is an increased risk of opportunistic infections in patients with PsA, and this risk is increased further with targeted biologic therapy.<b>Areas covered</b>: This paper reviews the role of the interleukin (IL)-12, IL-23 and IL-17 axis in the pathogenesis of PsA. 31847608 2020
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 AlteredExpression disease BEFREE In comparison with PsA, AA was associated with higher levels of IL-17F, IL-17E and IL-23. 30980732 2020
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Genetic associations imply a role for CD8+ T cells and the IL-23/IL-17 axis in psoriatic arthritis (PsA) and other spondyloarthritides (SpA). 31677365 2020
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Thus, these cells likely to be a part of the IL-23/IL-17A cytokine network and play a critical role in the pathogenesis of PsA. 31541902 2020
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Despite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti-Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL-23/IL-17 pathway often provide prolonged, deep responses and in some cases even remission (3). 31736273 2020
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE IL-23 is important in the proliferation and maintenance of IL-17, and therefore, cytokines of the IL-23/IL-17 axis attracted much interest as therapeutic targets in psoriasis and PsA. 31447673 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 GeneticVariation disease BEFREE The association to PsA was observed in the presence of polymorphisms: TNF-238 G > A (rs361525), -308 G > A (rs1800629), and -857 C > T (rs1799724); IL12B C > G (rs6887695) and A > C (rs3212227); IL23A A > G (rs2066808) and IL23R G > A (rs11209026). 30584776 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Clinical trials have reported the effectiveness of numerous biologics with different targets, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-17 receptor, IL-12/23(p40), and IL-23(p19) for the treatment of PsA. 30891646 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome. 30858782 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Thus, these Ad.scIL-23-treated mice represent a physiologically relevant model of psoriatic arthritis for understanding disease progression and for testing therapeutic approaches.-Flores, R. R., Carbo, L., Kim, E., Van Meter, M., De Padilla, C. M. L., Zhao, J., Colangelo, D., Yousefzadeh, M. J., Angelini, L. A., Zhang, L., Pola, E., Vo, N., Evans, C. H., Gambotto, A., Niedernhofer, L. J., Robbins, P. D. Adenoviral gene transfer of a single-chain IL-23 induces psoriatic arthritis-like symptoms in NOD mice. 31170010 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE In recent years, interleukin (IL)-12/IL-23 inhibitors have entered clinical practice as a new class of drug for the treatment of PsA, with some data suggesting a lower effect of body weight on their effectiveness. 31264033 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Interleukin-17A (IL-17A), IL-17F, IL-23, and CRP concentrations were measured in serum samples collected as part of the 2 PSUMMIT phase III studies of ustekinumab in PsA (n = 927). 31070869 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Two independent authors searched the databases PubMed and EMBASE for studies reporting on adverse events in phase 3 trials of IL-17 and IL-23 inhibitors for patients with psoriasis and psoriatic arthritis. 31721310 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE In this review, we will discuss recent advances on the cellular and molecular pathophysiological mechanisms that regulate the initiation and progression of PsA as well as new therapeutic approaches for IL-23/IL-23R targeted therapeutics. 30196070 2019
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE The IL-23/Th17 axis has been implicated in the development of autoimmune diseases, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). 29148561 2018
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 AlteredExpression disease BEFREE In the study, a higher level of IL-17 and IL-23 was also shown in patients with psoriatic arthritis in comparison to patients with normal psoriasis. 30206447 2018
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 AlteredExpression disease BEFREE In this study we show that psoriatic arthritis (PsA), a severe disease of the joints depending on the activation of the IL-23/IL-17 pathway, is characterized by a skewed ILC homeostasis. 29330320 2018
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. 30172115 2018
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Perturbation of the IL-23/Th17 axis instigates Th17-mediated inflammation in R26Stat3C<sup>stopfl/fl</sup> CD4Cre mice, leading to cutaneous and synovio-entheseal inflammation and bone pathologic features highly reminiscent of human PsA. 29439292 2018
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE The IL-23/IL-17 axis is central to the pathogenesis of psoriatic arthritis (PsA). 29148410 2018
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE The unique bone phenotype that occurs in PsA and AS is a surprising coexistence of both systemic bone loss and periosteal and entheseal bone formation and is likely to be the result of the actions of IL-23 and/or IL-17 on bone. 30266977 2018
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE The IL-23/IL-17 axis plays a critical pathogenic role for both PsA and Ps, and biologics neutralizing IL-17A or IL-23/IL-12 are effective therapies for PsA and Ps. 27666819 2017
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE The cytokines interleukin (IL)-12 and IL-23 have been involved in the pathogenesis of psoriasis and psoriatic arthritis. 28441904 2017
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Furthermore, polymorphisms of <i>IL23R</i> are a risk factor for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), which indicates that IL-23 is also involved in the pathogenesis of spondyloarthritis (SpA). 28850053 2017
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.100 Biomarker disease BEFREE Psoriatic arthritis (PsA) can be treated using biologic therapies targeting biomolecules such as tumor necrosis factor alpha, interleukins (IL)-17 and IL-23. 26108918 2016